Serina Therapeutics Inc SER 深 滬
等待開盤 06-03 09:30:00 美东时间
1.76
-0.050
-2.76%
華盛通- 最 高1.79
- 今 開1.76
- 成交量 2.07万股
- 最 低 1.76
- 昨 收 1.81
- 總市值 2639.56万
- 52周最高 7.92
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 1.22
- 委 比 -33.33%
- 總股本 1499.75万
- 歷史最高 209.2615
- 量 比 0.32
- 振 幅 1.66%
- 歷史最低 1.22
- 每 手 1
- 風險率 1.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1708599/000149315226025007/forms-3.htm
05-23 04:04
Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027
SER-252 Phase 1b Registrational Clinical Study: Following dosing of the first patient in February 2026, Serina continues to advance its Phase 1b registrational clinical study of SER-252 in advanced Parkinson's disease.
05-15 05:52
Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) Estimate
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.44) by 31.82 percent. This is a 18.37 percent decrease over losses of $(0.49) per share
05-15 04:43
Serina Therapeutics presents POZ-based lipid nanoparticle data at LNP formulation summit
Serina Therapeutics presents POZ-based lipid nanoparticle data at LNP formulation summit Serina to present at 5th LNP Formulation & Process Development Summit in Boston, Massachusetts. Event scheduled for April 7, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using gene
04-07 18:46
Serina Therapeutics Q4 EPS $(0.31) Beats $(0.46) Estimate
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.46) by 32.61 percent. This is a 29.17 percent decrease over losses of $(0.24) per share from
03-26 04:37
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why
Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.
03-19 15:11
Serina Therapeutics Announces Up To $30M In Private Placement To Support Registrational Trial Of SER-252 Parkinson's Treatment
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at
03-19 04:13
Serina Therapeutics enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease
Serina Therapeutics enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease Serina Therapeutics said it has enrolled the first patient in a global Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease. The study will evaluate safety, tol
02-19 19:00
Why DarkIris Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Shares of DarkIris Inc (NASDAQ:DKI) rose sharply in pre-market trading after th...
02-02 18:17
